We are live on ! Find out more
LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings

14 hedge funds and large institutions have $9.26M invested in LAVA Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $8.47M → $9.26M (+$793K)

0.54% more ownership

Funds ownership: 21.75% → 22.29% (+0.54%)

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
5
Closed
2
Calls
$34K
Puts
–
Net Calls
+$34K
Net Calls Change
+$9K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$1.2M
2
Morgan Stanley
Morgan Stanley
New York
+$56.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$30.8K

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$745K
2
AG
Artal Group
Luxembourg
-$294K
3
Millennium Management
Millennium Management
New York
-$51.3K
4
AWG
Alpha Wave Global
New York
-$1.7K
5
TRCT
Tower Research Capital (TRC)
New York
-$714
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
1
Redmile Group
California
$3.28M – – –
NHAS
2
Novo Holdings A/S
Denmark
$2.97M -$745K -521,806 -22%
TCM
3
Tang Capital Management
California
$1.33M +$1.2M +840,593 New
BC
4
Bruce & Co
Illinois
$1.22M – – –
AWG
5
Alpha Wave Global
New York
$170K -$1.7K -1,191 -1%
PNC Financial Services Group
6
PNC Financial Services Group
Pennsylvania
$103K – – –
Morgan Stanley
7
Morgan Stanley
New York
$78.4K +$56.1K +39,300 +382%
Millennium Management
8
Millennium Management
New York
$44.3K -$51.3K -35,946 -56%
Citadel Advisors
9
Citadel Advisors
Florida
$34.1K +$30.8K +21,552 New
TRCT
10
Tower Research Capital (TRC)
New York
$18.1K -$714 -500 -4%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$17.6K – – –
TFGT
12
TS Financial Group (TSFG)
Illinois
$1K – – –
Group One Trading
13
Group One Trading
Illinois
$158 – – –
AG
14
Artal Group
Luxembourg
– -$294K -200,000 Closed
Simplex Trading
15
Simplex Trading
Illinois
– -$334 -234 -35%
Osaic Holdings
16
Osaic Holdings
Arizona
– -$71 -48 Closed

LVTX Hedge Fund Activity: Q4 2023 in Review

14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q4 2023, worth a combined $9.26M — up 9.4% from $8.47M a quarter earlier.

Fund positioning in LVTX was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 5 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $1.2M. The largest seller was Novo Holdings A/S, cutting an estimated $745K.

  • 14 institutional investors held LAVA Therapeutics (LVTX) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $9.26M of LAVA Therapeutics stock for Q4 2023, up 9.4% quarter-over-quarter.
  • 2 funds opened new LAVA Therapeutics positions in Q4 2023 and 2 closed out, a net change of 0 holders.
  • The largest LAVA Therapeutics buyer in Q4 2023 was Tang Capital Management, an estimated $1.2M added.
  • The largest LAVA Therapeutics seller in Q4 2023 was Novo Holdings A/S, an estimated $745K sold.

Based on aggregated 13F filings for Q4 2023.